NCT05221372View on ClinicalTrials.gov

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

RecruitingOBSERVATIONAL
Enrollment

1,300

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

January 1, 2031

Study Completion Date

January 1, 2031

Conditions
Non Small Cell Lung CancerLiquid BiopsyTyrosine Kinase Inhibitor
Trial Locations (1)

Unknown

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT05221372 - ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI) | Biotech Hunter | Biotech Hunter